|
🐜
|
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
18 auth.
C. Polman,
S. Reingold,
B. Banwell,
M. Clanet,
Jeffrey A. Cohen,
M. Filippi,
K. Fujihara,
E. Havrdová,
M. Hutchinson,
L. Kappos,
...
F. Lublin,
X. Montalban,
P. O'Connor,
M. Sandberg-wollheim,
A. Thompson,
E. Waubant,
B. Weinshenker,
J. Wolinsky
|
13 |
2011 |
13
🐜
|
|
🐜
|
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
14 auth.
C. Polman,
P. W. O'connor,
E. Havrdová,
M. Hutchinson,
L. Kappos,
David H. Miller,
J. Phillips,
F. Lublin,
G. Giovannoni,
A. Wajgt,
...
M. Toal,
F. Lynn,
M. Panzara,
A. Sandrock
|
11 |
2006 |
11
🐜
|
|
🐜
|
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
13 auth.
R. Fox,
David H. Miller,
J. Phillips,
M. Hutchinson,
E. Havrdová,
M. Kita,
Minhua Yang,
K. Raghupathi,
M. Novas,
M. Sweetser,
...
V. Viglietta,
K. Dawson,
C. Sindic
|
10 |
2012 |
10
🐜
|
|
🐜
|
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
23 auth.
Mellen Center,
J. A. Cohen,
Md,
Canada,
L. Arnold,
E. Fox,
Jeff Rey,
A. Cohen,
A. Coles,
Douglas L Arnold,
...
C. Confavreux,
E. Fox,
H. Hartung,
E. Havrdová,
Krzysztof W Selmaj,
Howard L. Weiner,
E. Fisher,
Vesna V. Brinar,
G. Giovannoni,
M. Stojanovic,
Bella I Ertik,
S. Lake,
D. Margolin
|
10 |
2012 |
10
🐜
|
|
🐜
|
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
19 auth.
A. Coles,
C. Twyman,
D. Arnold,
Jeffrey A. Cohen,
C. Confavreux,
E. Fox,
H. Hartung,
E. Havrdová,
K. Selmaj,
H. Weiner,
...
T. Miller,
E. Fisher,
R. Sandbrink,
R. Sandbrink,
S. Lake,
D. Margolin,
P. Oyuela,
M. Panzara,
D. Compston
|
10 |
2012 |
10
🐜
|
|
🐜
|
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
16 auth.
L. Kappos,
R. Gold,
David H. Miller,
D. MacManus,
E. Havrdová,
V. Limmroth,
C. Polman,
K. Schmierer,
T. Yousry,
Minhua Yang,
...
M. Eraksoy,
E. Meluzínová,
I. Rektor,
K. Dawson,
A. Sandrock,
G. O'neill
|
8 |
2008 |
8
🐜
|
|
🦁
|
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
13 auth.
E. Havrdová,
S. Galetta,
M. Hutchinson,
D. Stefoski,
D. Bates,
C. Polman,
Paul W. O’Connor,
G. Giovannoni,
J. Phillips,
F. Lublin,
...
A. Pace,
R. Kim,
R. Hyde
|
8 |
2009 |
8
🦁
|
|
🐜
|
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
27 auth.
X. Montalban,
R. Gold,
A. Thompson,
Susana Otero-Romero,
M. Amato,
Dhia Chandraratna,
M. Clanet,
G. Comi,
T. Derfuss,
F. Fazekas,
H. Hartung,
E. Havrdová,
B. Hemmer,
L. Kappos,
R. Liblau,
...
C. Lubetzki,
Elena Marcus,
David H. Miller,
T. Olsson,
S. Pilling,
K. Selmaj,
A. Siva,
P. Sørensen,
M. Sormani,
C. Thalheim,
H. Wiendl,
F. Zipp
|
8 |
2018 |
8
🐜
|
|
🐜
|
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
40 auth.
J. W. Brown,
A. Coles,
D. Horáková,
E. Havrdová,
G. Izquierdo,
A. Prat,
M. Girard,
P. Duquette,
M. Trojano,
A. Lugaresi,
R. Bergamaschi,
P. Grammond,
R. Alroughani,
R. Hupperts,
P. Mccombe,
...
V. van Pesch,
P. Sola,
D. Ferraro,
F. Grand'Maison,
M. Terzi,
J. Lechner-Scott,
S. Flechter,
M. Slee,
V. Shaygannejad,
E. Pucci,
F. Granella,
V. Jokubaitis,
M. Willis,
C. Rice,
N. Scolding,
A. Wilkins,
O. Pearson,
T. Ziemssen,
M. Hutchinson,
K. Harding,
Joanne L. Jones,
C. McGuigan,
H. Butzkueven,
T. Kalincik,
N. Robertson
|
8 |
2019 |
8
🐜
|
|
🐜
|
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
29 auth.
L. Kappos,
D. Bates,
G. Edan,
M. Eraksoy,
A. García‐Merino,
N. Grigoriadis,
H. Hartung,
E. Havrdová,
J. Hillert,
R. Hohlfeld,
M. Kremenchutzky,
O. Lyon‐Caen,
Ariel Miller,
C. Pozzilli,
M. Ravnborg,
...
T. Saida,
C. Sindic,
K. Vass,
D. Clifford,
S. Hauser,
E. Major,
P. O'Connor,
H. Weiner,
M. Clanet,
R. Gold,
H. Hirsch,
E. Radü,
P. Sørensen,
J. King
|
8 |
2007 |
8
🐜
|
|
🐜
|
Defining secondary progressive multiple sclerosis.
45 auth.
Johannes Lorscheider,
K. Buzzard,
V. Jokubaitis,
T. Spelman,
E. Havrdová,
D. Horáková,
M. Trojano,
G. Izquierdo,
M. Girard,
P. Duquette,
A. Prat,
A. Lugaresi,
F. Grand'Maison,
P. Grammond,
R. Hupperts,
...
R. Alroughani,
P. Sola,
C. Boz,
E. Pucci,
Jeanette Lechner-Scott,
R. Bergamaschi,
C. Oreja-Guevara,
G. Iuliano,
V. van Pesch,
F. Granella,
C. Ramo-Tello,
D. Spitaleri,
T. Petersen,
M. Slee,
F. Verheul,
R. Ampapa,
M. Amato,
P. Mccombe,
S. Vucic,
J. L. Sánchez Menoyo,
E. Cristiano,
M. Barnett,
S. Hodgkinson,
J. Olascoaga,
M. Saladino,
O. Gray,
C. Shaw,
F. Moore,
H. Butzkueven,
T. Kalincik
|
8 |
2016 |
8
🐜
|
|
🐜
|
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
20 auth.
D. Miller,
D. Soon,
K. Fernando,
D. MacManus,
G. Barker,
T. Yousry,
E. Fisher,
P. O'Connor,
J. Phillips,
C. Polman,
...
L. Kappos,
M. Hutchinson,
E. Havrdová,
F. Lublin,
G. Giovannoni,
A. Wajgt,
R. Rudick,
F. Lynn,
M. Panzara,
A. Sandrock
|
8 |
2007 |
8
🐜
|
|
🐜
|
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
27 auth.
X. Montalban,
R. Gold,
A. Thompson,
Susana Otero-Romero,
M. Amato,
Dhia Chandraratna,
M. Clanet,
G. Comi,
T. Derfuss,
F. Fazekas,
Hans-Peter Hartung,
E. Havrdová,
B. Hemmer,
L. Kappos,
R. Liblau,
...
C. Lubetzki,
Elena Marcus,
David H. Miller,
T. Olsson,
S. Pilling,
K. Selmaj,
A. Siva,
P. Sørensen,
M. Sormani,
C. Thalheim,
H. Wiendl,
F. Zipp
|
8 |
2018 |
8
🐜
|
|
🐜
|
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
12 auth.
R. Gold,
G. Giovannoni,
K. Selmaj,
E. Havrdová,
X. Montalban,
E. Radue,
...
D. Stefoski,
Randy R. Robinson,
K. Riester,
J. Rana,
J. Elkins,
G. O'neill
|
8 |
2013 |
8
🐜
|
